PLoS ONE
(Jan 2024)
Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective
- Nimer S. Alkhatib,
- Abdulaali R. Almutairi,
- Majid Almadi,
- Shiraz Halloush,
- Yazed Sulaiman H. Al-Ruthia,
- Omar Rashdan,
- Samah Al-Shatnawi,
- Nahla A. Azzam,
- Mahmoud H. Mosli,
- Amal M. Badawoud,
- Majed S. Al Yami,
- Abdulaziz Alhossan,
- Ibtisam AlHarbi
Affiliations
- Nimer S. Alkhatib
- Abdulaali R. Almutairi
- Majid Almadi
- Shiraz Halloush
- Yazed Sulaiman H. Al-Ruthia
- Omar Rashdan
- Samah Al-Shatnawi
- Nahla A. Azzam
- Mahmoud H. Mosli
- Amal M. Badawoud
- Majed S. Al Yami
- Abdulaziz Alhossan
- Ibtisam AlHarbi
- Journal volume & issue
-
Vol. 19,
no. 11
WeChat QR code